

- Subsequent course, as indicated by **ALL** of the following^[D]:
 - Age 18 years or older
 - Favorable response to prior administration of certolizumab
- ☐ Crohn disease, as indicated by **1 or more** of the following(24)(25)(26)(27)(28):^N
- Initial course, as indicated by **ALL** of the following^[E](34):
 - Age 18 years or older
 - Disease activity, as indicated by **1 or more** of the following:
 - Moderate to severe active Crohn disease,^[F] as indicated by **1 or more** of the following(24)(27)(37):
 - Anemia
 - Dehydration
 - Elevated serum C-reactive protein level
 - Fever
 - Intermittent vomiting
 - Perianal or rectal disease on endoscopy(38)(39)
 - Weight loss of greater than 10% of body weight
 - Perianal fistula(24)(31)(39)
 - Intolerance or inadequate response to therapy with **1 or more** of the following(24):
 - 6-mercaptopurine
 - Azathioprine
 - Methotrexate
 - Oral corticosteroids
 - Subsequent course, as indicated by **ALL** of the following^[G]:
 - Age 18 years or older
 - Favorable response to prior administration of certolizumab
- ☐ Plaque psoriasis, as indicated by **1 or more** of the following(4)(40)(41)(42):^N
- Initial course, as indicated by **ALL** of the following^[H]:
 - Age 18 years or older
 - Moderate to severe plaque psoriasis, as indicated by **ALL** of the following(44)(45)(46)(47)(48):
 - Candidate for systemic therapy or phototherapy
 - Clinical need for systemic treatment, as indicated by **1 or more** of the following:
 - Body surface area involvement of 10% or more
 - Involvement of scalp, face, feet, hands, or genitalia that impacts patient quality of life
 - Failure of other treatments to control psoriasis, as indicated by **1 or more** of the following(44)(45):
 - Immunosuppressive treatments (eg, cyclosporine, methotrexate)
 - Photochemotherapy (ie, psoralen plus ultraviolet A therapy)(49)
 - Phototherapy (ie, ultraviolet light therapy)(49)
 - Topical agents (eg, anthralin, calcipotriene, coal tars, corticosteroids, tazarotene)(45)
 - Tumor necrosis factor inhibitor(50)
 - Subsequent course, as indicated by **ALL** of the following^[I]:
 - Age 18 years or older
 - Favorable response to prior administration of certolizumab
- ☐ Psoriatic arthritis, as indicated by **1 or more** of the following(4)(5)(51)(52)(53):^N
- Initial course, as indicated by **ALL** of the following^[J]:
 - Age 18 years or older
 - Active arthritis, as indicated by **1 or more** of the following:
 - Axial disease with inflammatory back pain, and failure of or intolerance to NSAIDs
 - Dactylitis^[K]
 - Enthesitis^[L] that is tender on examination
 - Peripheral disease with one or more tender and swollen joints, and failure of, intolerance to, or contraindication to methotrexate
 - Inadequate response, intolerance, or contraindication to 3 or more months of treatment with NSAIDs
 - Subsequent course, as indicated by **ALL** of the following^[M]:
 - Age 18 years or older
 - Favorable response to prior administration of certolizumab
- ☐ Rheumatoid arthritis, as indicated by **1 or more** of the following(58)(59)(60)(61)(62):^N
- Initial course, as indicated by **ALL** of the following^[N](80)(81):
 - Age 18 years or older
 - Inadequate response to 3 or more months of treatment with disease-modifying antirheumatic drug, including **1 or more** of the following(59)(60)(82)(83)(84):
 - Hydroxychloroquine

- Leflunomide
- Methotrexate
- Sulfasalazine
- Tumor necrosis factor inhibitor(82)(83)(85)
- Moderate to severe active rheumatoid arthritis,^[O] as indicated by **1 or more** of the following(86)(87)(88):
 - Clinical Disease Activity Index^[P] score greater than 10
 - Disease Activity Score^[Q] of 3.2 or greater
 - Patient Activity Scale^[R] of 3.71 or greater
 - Patient Activity Scale-III^[R] of 3.71 or greater
 - Routine Assessment of Patient Index Data 3^[S] score greater than 2
 - Simplified Disease Activity Index^[T] score greater than 11
- Subsequent course, as indicated by **ALL** of the following^[U]:
 - Age 18 years or older
 - Favorable response to prior administration of certolizumab
- Hepatitis B HBsAg negative, or concurrent treatment with antiviral therapy^[V](84)(89)
- No active serious infection(90)(91)(92)(93)
- No concurrent treatment with anakinra, abatacept, rituximab, natalizumab, or another tumor necrosis factor inhibitor
- No concurrent use of live vaccine^[W](58)(94)(95)
- No untreated latent or active tuberculosis(90)(93)(96)(97)

Evidence Summary

Background

Certolizumab is a recombinant anti-tumor necrosis factor-alpha monoclonal antibody that reduces the inflammatory response.(1)(4) **(EG 2)**

Criteria

For axial spondyloarthritis (ankylosing spondylitis, nonradiographic axial spondyloarthritis), evidence demonstrates at least moderate certainty of at least moderate net benefit. **(RG A1)** In a double-blind randomized controlled trial of 325 adult patients with active axial spondyloarthritis, administration of certolizumab every 2 or 4 weeks was associated with significant and rapid improvement in Assessment of SpondyloArthritis international Society 20 (ASAS20) score at 12 weeks as compared with placebo (58% when given every 2 weeks, 64% when given every 4 weeks, and 38% for placebo); at 24 weeks, patients in the combined certolizumab arms showed significant improvement in secondary outcomes, including the Bath Ankylosing Spondylitis Functional Index, Disease Activity Index, and Metrology Index.(9) **(EG 1)** No deaths or malignancies were reported in this study, and no additional adverse safety information was noted as compared with administration in patients with rheumatoid arthritis.(9) **(EG 1)** A meta-analysis and a systematic review of the use of biologics for ankylosing spondylitis have found that certolizumab and similar drugs were effective in improving some extra-articular disease manifestations, including uveitis.(10)(11) **(EG 1)** A randomized study has demonstrated longer-term efficacy for up to 96 weeks.(12) **(EG 1)** A randomized trial of 317 adult patients with active nonradiographic axial spondyloarthritis compared treatment with certolizumab or placebo (both could be combined with nonbiologic medications) and found, at 1-year follow-up, that certolizumab was associated with more patients achieving a 2-point or more improvement in Ankylosing Spondylitis Disease Activity Score (ASDAS) and a 40% improvement in Assessment of SpondyloArthritis international Society (ASAS40) scores compared with placebo.(13) **(EG 1)** An open-label extension of this study including 243 patients (all patients received certolizumab starting at week 52) found that clinical improvements were maintained at 3-year follow-up.(14) **(EG 2)**

For Crohn disease, evidence demonstrates at least moderate certainty of at least moderate net benefit. **(RG A1)** Systematic reviews and meta-analyses have concluded that certolizumab is moderately effective for the induction and maintenance of disease remission.(29)(30) **(EG 1)** A subgroup analysis from a randomized trial reported efficacy of certolizumab for closure of perianal fistulas in Crohn disease.(31) **(EG 1)** Extension studies have demonstrated continuing efficacy and safety for up to 7 years of administration.(32) **(EG 2)** An open-label study of 539 patients with Crohn disease reported that 62% of patients had a significant response with certolizumab when refractory to infliximab therapy.(33) **(EG 2)** Practice guidelines recommend that tumor necrosis factor inhibitors such as certolizumab are indicated for Crohn disease in patients who have not responded to standard therapy (ie, a "step-up" approach).(34) (35) **(EG 2)** Expert opinion has also suggested that early use of tumor necrosis factor inhibitors in combination with immunomodulators (ie, a "top-down" approach) may be an effective treatment strategy in patients with severe disease.(24)(28)(36) **(EG 2)**

For plaque psoriasis, evidence demonstrates at least moderate certainty of at least moderate net benefit. **(RG A1)** Two phase III randomized trials (461 patients with moderate to severe chronic plaque psoriasis) compared treatment with certolizumab at 2 dosage strengths with placebo and found, at 16 weeks, that certolizumab at either dose was associated with more patients achieving 75% improvement in Psoriasis Area and Severity Index (PASI 75) scores and Physician's Global Assessment (PGA) scores of clear or almost clear; these results were maintained at 48-week follow-up.(40) **(EG 1)** An open-label extension of these trials (433 patients, all treated with certolizumab by 48 weeks) found, at 144-week follow-up, that PASI 75 and PGA scores of clear or almost clear were maintained.(43) **(EG 2)** A phase III randomized trial (559 patients with moderate to severe chronic plaque psoriasis) compared treatment with certolizumab (at 2 dosage strengths), etanercept, and placebo and found, at 12-week follow-up, that certolizumab at

either dose was associated with more patients achieving 75% improvement in Psoriasis Area and Severity Index (PASI 75) scores compared with placebo. Certolizumab at 400 mg every other week was associated with higher PASI 75 scores compared with etanercept, and certolizumab at 200 mg every other week was found to be noninferior to etanercept.(41) **(EG 1)**

For psoriatic arthritis, evidence demonstrates at least moderate certainty of at least moderate net benefit. **(RG A1)** In a randomized controlled trial of 409 adult patients with active psoriatic arthritis, of whom 368 completed 24 weeks of treatment, administration of certolizumab every 2 or 4 weeks was associated with significant and rapid improvement in American College of Rheumatology 20% improvement criteria (ACR20) score as compared with placebo (58% when given every 2 weeks, 52% when given every 4 weeks, and 24% for placebo); patients in the combined certolizumab arms showed significant improvement in secondary outcomes, including physical function, psoriatic skin involvement, enthesitis, dactylitis, and nail disease. No additional significant adverse safety information was noted.(54) **(EG 1)** In an open-label continuation study, 183 patients continued certolizumab for 216 weeks; improvements in joint disease (measured by the ACR20, ACR50, and ACR70), disease activity (measured by the Disease Activity Index for Psoriatic Arthritis), skin involvement (measured by the Psoriasis Area and Severity Index), and enthesitis, dactylitis, and nail psoriasis were all maintained through the treatment period.(55) **(EG 2)** Randomized controlled trials have indicated significant improvement in work productivity and participation in social activities in patients with psoriatic arthritis after therapy with certolizumab.(56) **(EG 2)**

For rheumatoid arthritis, evidence demonstrates at least moderate certainty of at least moderate net benefit. **(RG A1)** Technology assessments and systematic reviews with meta-analysis of randomized trials have concluded that certolizumab is an effective treatment option for moderate to severe disease.(62)(63)(64) **(EG 1)** A practice guideline, systematic reviews, and meta-analyses recommend that biological therapy, such as certolizumab, is indicated for patients who fail first-line therapy with methotrexate or other disease-modifying antirheumatic drugs.(59)(61)(65)(66)(67) **(EG 1)** A network meta-analysis of 67 randomized controlled trials (20,898 patients) evaluating the efficacy and safety of antirheumatic therapies for rheumatoid arthritis concluded that the combination of certolizumab and methotrexate ranked highest in clinical efficacy; due to the relatively low risk of adverse events, the combination was recommended as the best therapy for rheumatoid arthritis.(68) **(EG 1)** A randomized controlled trial of 316 patients with early rheumatoid arthritis and poor prognostic factors compared initial therapy with methotrexate combined with either certolizumab or placebo and found, at 24-week and 52-week follow-up, that certolizumab was associated with greater inhibition of radiographic progression compared with placebo.(69) **(EG 1)** A similar randomized controlled study with 879 such patients found that administration of certolizumab plus methotrexate was associated with significantly greater rates of sustained remission and low disease activity, as well as improved physical function and reduced structural damage at 40 and 52 weeks, as compared with placebo plus methotrexate.(70) **(EG 1)** Concerns exist regarding the potential development of malignancy in patients with rheumatoid arthritis receiving biological therapies including tumor necrosis factor inhibitors such as certolizumab. However, a meta-analysis of 29,423 patients from 63 randomized controlled trials reported that the use of such biological therapies for at least 6 months' duration was not significantly associated with an increased risk of malignancy, as compared with other nonbiological disease-modifying antirheumatic drugs or with placebo.(71) **(EG 1)** Indirect comparisons of certolizumab with other biological agents have shown comparable efficacy, especially when administered with methotrexate.(72)(73)(74)(75)(76)(77) **(EG 1)** A multiple treatment comparison regression analysis estimated that certolizumab was the most effective of the biologics tested in terms of achieving American College of Rheumatology 50% improvement criteria (ACR50) score, whether given with or without disease-modifying drugs.(78) **(EG 2)**

References

1. Cimzia (certolizumab pegol) for injection. Physician Prescribing Information [Internet] UCB, Inc. 2019 Sep Accessed at: <https://cimzia.com/>. [created 2008; accessed 2022 Nov 11] [Context Link 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13]
2. Willrich MA, Murray DL, Snyder MR. Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases. *Translational Research* 2015;165(2):270-282. DOI: 10.1016/j.trsl.2014.09.006. [Context Link 1] View abstract...
3. Deeks ED. Certolizumab pegol: a review in inflammatory autoimmune diseases. *BioDrugs* 2016;30(6):607-617. DOI: 10.1007/s40259-016-0197-y. [Context Link 1] View abstract...
4. Esposito M, Carubbi F, Giunta A, Alunno A, Giacomelli R, Fargnoli MC. Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis. *Expert Review of Clinical Immunology* 2020;16(2):119-128. DOI: 10.1080/1744666X.2020.1713754. [Context Link 1, 2, 3] View abstract...
5. Dhillon S. Certolizumab pegol: a review of its use in patients with axial spondyloarthritis or psoriatic arthritis. *Drugs* 2014;74(9):999-1016. DOI: 10.1007/s40265-014-0239-z. [Context Link 1, 2] View abstract...
6. TNF-Alpha Inhibitors for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis. NICE Technology Appraisal Guidance TA383 [Internet] National Institute for Health and Care Excellence. 2016 Feb (NICE reviewed 2019) Accessed at: <https://www.nice.org.uk/guidance/>. [accessed 2022 Oct 24] [Context Link 1, 2]
7. Desmarais J, Beier S, Deodhar A. Certolizumab pegol for treating axial spondyloarthritis. *Expert Opinion on Biological Therapy* 2016;16(8):1059-1064. DOI: 10.1080/14712598.2016.1205581. [Context Link 1] View abstract...
8. Klavdianou K, Tsiami S, Baraliakos X. New developments in ankylosing spondylitis-status in 2021. *Rheumatology* 2021;60(Suppl 6):vi29-vi37. DOI: 10.1093/rheumatology/keab523. [Context Link 1] View abstract...
9. Landewe R, et al. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. *Annals of the Rheumatic Diseases* 2014;73(1):39-47. DOI: 10.1136/annrheumdis-2013-204231. [Context Link 1, 2] View abstract...
10. Wu D, et al. Efficacy of anti-tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta-analysis. *BMC Musculoskeletal Disorders* 2015;16:19. DOI: 10.1186/s12891-015-0489-2. [Context Link 1] View abstract...

11. Corbett M, et al. Tumour necrosis factor- α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. *Health Technology Assessment* 2016;20(9):1-334. DOI: 10.3310/hta20090. [Context Link 1] View abstract...
12. Sieper J, et al. Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial. *Arthritis & Rheumatology* (Hoboken, N.J.) 2015;67(3):668-677. DOI: 10.1002/art.38973. [Context Link 1] View abstract...
13. Deodhar A, et al. A 52-week randomized placebo-controlled trial of certolizumab pegol in non-radiographic axial spondyloarthritis. *Arthritis & Rheumatology* (Hoboken, N.J.) 2019;71(7):1101-1111. DOI: 10.1002/art.40866. [Context Link 1] View abstract...
14. van der Heijde D, et al. Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study. *Rheumatic & Musculoskeletal Diseases Open* 2022;8(1):Online. DOI: 10.1136/rmdopen-2021-002138. [Context Link 1] View abstract...
15. van der Heijde D, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. *Annals of the Rheumatic Diseases* 2017;76(6):978-991. DOI: 10.1136/annrheumdis-2016-210770. (Reaffirmed 2022 Jul) [Context Link 1] View abstract...
16. Ward MM, et al. 2019 update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. *Arthritis & Rheumatology* (Hoboken, N.J.) 2019;71(10):1599-1613. DOI: 10.1002/art.41042. (Reaffirmed 2022 Jul) [Context Link 1] View abstract...
17. Ghosh N, Ruderman EM. Nonradiographic axial spondyloarthritis: clinical and therapeutic relevance. *Arthritis Research & Therapy* 2017;19(1):286. DOI: 10.1186/s13075-017-1493-8. [Context Link 1] View abstract...
18. Navarro-Compan V, Sepriano A, El-Zorkany B, van der Heijde D. Axial spondyloarthritis. *Annals of the Rheumatic Diseases* 2021;80(12):1511-1521. DOI: 10.1136/annrheumdis-2021-221035. [Context Link 1] View abstract...
19. Poddubnyy D. Classification vs diagnostic criteria: the challenge of diagnosing axial spondyloarthritis. *Rheumatology* 2020;59(Suppl4):iv6-iv17. DOI: 10.1093/rheumatology/keaa250. [Context Link 1] View abstract...
20. Walsh JA, Magrey M. Clinical manifestations and diagnosis of axial spondyloarthritis. *Journal of Clinical Rheumatology* 2021;27(8):e547-e560. DOI: 10.1097/RHU.0000000000001575. [Context Link 1] View abstract...
21. Sieper J, Poddubnyy D. Axial spondyloarthritis. *Lancet* 2017;390(10089):73-84. DOI: 10.1016/S0140-6736(16)31591-4. [Context Link 1] View abstract...
22. Reveille JD. Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis. *Clinical Rheumatology* 2015;34(6):1009-1018. DOI: 10.1007/s10067-015-2949-3. [Context Link 1] View abstract...
23. Braun J, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. *Annals of the Rheumatic Diseases* 2011;70(6):896-904. DOI: 10.1136/ard.2011.151027. (Reaffirmed 2022 May) [Context Link 1] View abstract...
24. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn's disease in adults. *American Journal of Gastroenterology* 2018;113(4):481-517. DOI: 10.1038/ajg.2018.27. (Reaffirmed 2022 Jul) [Context Link 1, 2, 3, 4, 5, 6] View abstract...
25. Levin AD, Wildenberg ME, van den Brink GR. Mechanism of action of anti-TNF therapy in inflammatory bowel disease. *Journal of Crohn's & Colitis* 2016;10(8):989-997. DOI: 10.1093/ecco-jcc/jjw053. [Context Link 1] View abstract...
26. Gionchetti P, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 2: surgical management and special situations. *Journal of Crohn's & Colitis* 2017;11(2):135-149. DOI: 10.1093/ecco-jcc/jjw169. (Reaffirmed 2022 Jul) [Context Link 1] View abstract...
27. Feuerstein JD, et al. AGA clinical practice guidelines on the medical management of moderate to severe luminal and perianal fistulizing Crohn's disease. *Gastroenterology* 2021;160(7):2496-2508. DOI: 10.1053/j.gastro.2021.04.022. (Reaffirmed 2022 Aug) [Context Link 1, 2, 3] View abstract...
28. Peyrin-Biroulet L, et al. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. *Therapeutic Advances in Gastroenterology* 2021;14:Online. DOI: 10.1177/17562848211059954. [Context Link 1, 2] View abstract...
29. Yamazaki H, et al. Certolizumab pegol for induction of remission in Crohn's disease. *Cochrane Database of Systematic Reviews* 2019, Issue 8. Art. No.: CD012893. DOI: 10.1002/14651858.CD012893.pub2. [Context Link 1] View abstract...
30. Da W, Zhu J, Wang L, Lu Y. Efficacy and safety of certolizumab pegol for Crohn's disease: a systematic review and meta-analysis. *Advances in Therapy* 2013;30(5):541-553. DOI: 10.1007/s12325-013-0026-3. [Context Link 1] View abstract...
31. Schreiber S, Lawrance IC, Thomsen OO, Hanauer SB, Bloomfield R, Sandborn WJ. Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study. *Alimentary Pharmacology and Therapeutics* 2011;33(2):185-193. DOI: 10.1111/j.1365-2036.2010.04509.x. [Context Link 1, 2] View abstract...
32. Sandborn WJ, et al. Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSe 3 study. *Alimentary Pharmacology and Therapeutics* 2014;40(8):903-916. DOI: 10.1111/apt.12930. [Context Link 1] View abstract...
33. Sandborn WJ, et al. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. *Clinical Gastroenterology and Hepatology* 2010;8(8):688-695.e2. DOI: 10.1016/j.cgh.2010.04.021. [Context Link 1] View abstract...
34. D'Haens GR, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? *American Journal of Gastroenterology* 2011;106(2):199-213. DOI: 10.1038/ajg.2010.392. [Context Link 1, 2] View abstract...
35. Torres J, et al. ECCO guidelines on therapeutics in Crohn's disease: medical treatment. *Journal of Crohn's & Colitis* 2020;14(1):4-22. DOI: 10.1093/ecco-jcc/jjz180. [Context Link 1] View abstract...
36. Fasci Spurio F, Aratari A, Margagnoni G, Doddato MT, Papi C. Early treatment in Crohn's disease: do we have enough evidence to reverse the therapeutic pyramid? *Journal of Gastrointestinal and Liver Diseases* 2012;21(1):67-73. [Context Link 1] View abstract...

37. Gomollon F, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn's disease 2016: Part 1: diagnosis and medical management. *Journal of Crohn's & Colitis* 2017;11(1):3-25. DOI: 10.1093/ecco-jcc/jjw168. (Reaffirmed 2022 Jul) [Context Link 1, 2] View abstract...
38. Zalieckas JM. Treatment of perianal Crohn's disease. *Seminars in Pediatric Surgery* 2017;26(6):391-397. DOI: 10.1053/j.sempedsurg.2017.10.009. [Context Link 1] View abstract...
39. Steinhart AH, et al. Clinical practice guideline for the medical management of perianal fistulizing Crohn's disease: the Toronto consensus. *Inflammatory Bowel Diseases* 2019;25(1):1-13. DOI: 10.1093/ibd/izy247. [Context Link 1, 2] View abstract...
40. Gottlieb AB, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks from two phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). *Journal of the American Academy of Dermatology* 2018;79(2):302-314 e6. DOI: 10.1016/j.jaad.2018.04.012. [Context Link 1, 2] View abstract...
41. Lebwohl M, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). *Journal of the American Academy of Dermatology* 2018;79(2):266-276 e5. DOI: 10.1016/j.jaad.2018.04.013. [Context Link 1, 2] View abstract...
42. Lee A, Scott LJ. Certolizumab pegol: a review in moderate to severe plaque psoriasis. *BioDrugs* 2020;34(2):235-244. DOI: 10.1007/s40259-020-00416-z. [Context Link 1] View abstract...
43. Gordon KB, et al. Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2). *British Journal of Dermatology* 2021;184(4):652-662. DOI: 10.1111/bjd.19393. [Context Link 1] View abstract...
44. Menter A, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *Journal of the American Academy of Dermatology* 2019;80(4):1029-1072. DOI: 10.1016/j.jaad.2018.11.057. (Reaffirmed 2022 Jul) [Context Link 1, 2] View abstract...
45. Lebwohl M. Psoriasis. *Annals of Internal Medicine* 2018;168(7):ITC49-ITC64. DOI: 10.7326/AITC201804030. [Context Link 1, 2, 3] View abstract...
46. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. *Journal of the American Medical Association* 2020;323(19):1945-1960. DOI: 10.1001/jama.2020.4006. [Context Link 1] View abstract...
47. Stiff KM, Glines KR, Porter CL, Cline A, Feldman SR. Current pharmacological treatment guidelines for psoriasis and psoriatic arthritis. *Expert Review of Clinical Pharmacology* 2018;11(12):1209-1218. DOI: 10.1080/17512433.2018.1548277. [Context Link 1] View abstract...
48. Pariser DM, Kircik LH, Stein Gold LF. Treating psoriasis: patient assessment, treatment goals, and treatment options. *Cutis* 2019;103(4S):S4-S7. [Context Link 1] View abstract...
49. Elmets CA, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. *Journal of the American Academy of Dermatology* 2019;81(3):775-804. DOI: 10.1016/j.jaad.2019.04.042. (Reaffirmed 2022 Jul) [Context Link 1, 2] View abstract...
50. Elyoussfi S, Thomas BJ, Ciurtin C. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies. *Rheumatology International* 2016;36(5):603-612. DOI: 10.1007/s00296-016-3436-0. [Context Link 1] View abstract...
51. Raychaudhuri SP, Wilken R, Sukhov AC, Raychaudhuri SK, Maverakis E. Management of psoriatic arthritis: Early diagnosis, monitoring of disease severity and cutting edge therapies. *Journal of Autoimmunity* 2017;76:21-37. DOI: 10.1016/j.jaut.2016.10.009. [Context Link 1, 2, 3] View abstract...
52. Kerschbaumer A, et al. Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis. *Annals of the Rheumatic Diseases* 2020;79(6):778-786. DOI: 10.1136/annrheumdis-2020-217163. [Context Link 1] View abstract...
53. Gossec L, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. *Annals of the Rheumatic Diseases* 2020;79:700-712. (Reaffirmed 2022 Jul) [Context Link 1] View abstract...
54. Mease PJ, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). *Annals of the Rheumatic Diseases* 2014;73(1):48-55. DOI: 10.1136/annrheumdis-2013-203696. [Context Link 1] View abstract...
55. van der Heijde D, et al. 4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis. *Rheumatic & Musculoskeletal Diseases Open* 2018;4(1):e000582. DOI: 10.1136/rmdopen-2017-000582. [Context Link 1] View abstract...
56. Kavanaugh A, Gladman D, van der Heijde D, Purcaru O, Mease P. Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study. *Annals of the Rheumatic Diseases* 2015;74(1):44-51. DOI: 10.1136/annrheumdis-2014-205198. [Context Link 1] View abstract...
57. Durham LE, Taams LS, Kirkham BW. Psoriatic arthritis. *British Journal of Hospital Medicine* 2016;77(7):C102-C108. DOI: 10.12968/hmed.2016.77.7.C102. [Context Link 1, 2] View abstract...
58. Furst DE, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. *Annals of the Rheumatic Diseases* 2013;72 Suppl 2:ii2-ii34. DOI: 10.1136/annrheumdis-2013-203348. [Context Link 1, 2] View abstract...
59. Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. *Annals of the Rheumatic Diseases* 2020;79(6):685-699. DOI: 10.1136/annrheumdis-2019-216655. (Reaffirmed 2022 Jul) [Context Link 1, 2, 3] View abstract...
60. Kerschbaumer A, et al. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. *Annals of the Rheumatic Diseases* 2020;79(6):744-759. DOI: 10.1136/annrheumdis-2019-216656. [Context Link 1, 2] View abstract...

61. Nam JL, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. *Annals of the Rheumatic Diseases* 2017;76(6):1113-1136. DOI: 10.1136/annrheumdis-2016-210713. [Context Link 1, 2] View abstract...
62. Adalimumab, Etanercept, Infliximab, Certolizumab Pegol, Golimumab, Tocilizumab and Abatacept for Rheumatoid Arthritis Not Previously Treated with DMARDs or After Conventional DMARDs Only Have Failed. NICE Technology Appraisal Guidance TA375 [Internet] National Institute for Health and Care Excellence. 2016 Jan (NICE reviewed 2019) Accessed at: <https://www.nice.org.uk/guidance/>. [accessed 2022 Oct 22] [Context Link 1, 2, 3]
63. Ruiz Garcia V, Burls A, Cabello JB, Vela Casasempere P, Bort-Marti S, Bernal JA. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. *Cochrane Database of Systematic Reviews* 2017, Issue 9. Art. No.: CD007649. DOI: 10.1002/14651858.CD007649.pub4. [Context Link 1] View abstract...
64. Lee YH, Bae SC. Efficacy and safety of methotrexate plus certolizumab pegol or placebo in active rheumatoid arthritis : Meta-analysis of randomized controlled trials. *Zeitschrift fur Rheumatologie* 2017;76(6):528-534. DOI: 10.1007/s00393-016-0133-z. [Context Link 1] View abstract...
65. Punzi L, Lapadula G, Mathieu A. Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice. *BioDrugs* 2014;28 Suppl 1:25-37. DOI: 10.1007/s40259-013-0065-y. [Context Link 1] View abstract...
66. Hazlewood GS, Barnabe C, Tomlinson G, Marshall D, Devoe DJ, Bombardier C. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis. *Cochrane Database of Systematic Reviews* 2016, Issue 8. Art. No.: CD010227. DOI: 10.1002/14651858.CD010227.pub2. [Context Link 1] View abstract...
67. Singh JA, et al. Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis. *Cochrane Database of Systematic Reviews* 2016, Issue 5. Art. No.: CD012183. DOI: 10.1002/14651858.CD012183. [Context Link 1] View abstract...
68. Ma K, Li L, Liu C, Zhou L, Zhou X. Efficacy and safety of various anti-rheumatic treatments for patients with rheumatoid arthritis: a network meta-analysis. *Archives of Medical Science* 2019;15(1):33-54. DOI: 10.5114/aoms.2018.73714. [Context Link 1] View abstract...
69. Atsumi T, et al. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. *Annals of the Rheumatic Diseases* 2016;75(1):75-83. DOI: 10.1136/annrheumdis-2015-207511. [Context Link 1] View abstract...
70. Emery P, et al. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naive patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study. *Annals of the Rheumatic Diseases* 2017;76(1):96-104. DOI: 10.1136/annrheumdis-2015-209057. [Context Link 1] View abstract...
71. Lopez-Olivo MA, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. *Journal of the American Medical Association* 2012;308(9):898-908. DOI: 10.1001/2012.jama.10857. [Context Link 1] View abstract...
72. Jansen JP, Buckley F, Dejonckheere F, Ogale S. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analysis. *Health and Quality of Life Outcomes* 2014;12:102. DOI: 10.1186/1477-7525-12-102. [Context Link 1] View abstract...
73. Alfonso-Cristancho R, et al. Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysis. *Clinical Rheumatology* 2017;36(1):25-34. DOI: 10.1007/s10067-016-3435-2. [Context Link 1] View abstract...
74. Singh JA, et al. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis. *Cochrane Database of Systematic Reviews* 2017, Issue 3. Art. No.: CD012591. DOI: 10.1002/14651858.CD012591. [Context Link 1] View abstract...
75. Singh JA, et al. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis. *Cochrane Database of Systematic Reviews* 2017, Issue 5. Art. No.: CD012657. DOI: 10.1002/14651858.CD012657. [Context Link 1] View abstract...
76. Smolen JS, et al. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXCELERATE study. *Lancet* 2016;388(10061):2763-2774. DOI: 10.1016/S0140-6736(16)31651-8. [Context Link 1] View abstract...
77. Tarp S, et al. Defining the optimal biological monotherapy in rheumatoid arthritis: A systematic review and meta-analysis of randomised trials. *Seminars in Arthritis and Rheumatism* 2017;46(6):699-708. DOI: 10.1016/j.semarthrit.2016.09.003. [Context Link 1] View abstract...
78. Tveite IF, Natvig B, Gasemyr J, Meland N, Roine M, Klemp M. Comparing effects of biologic agents in treating patients with rheumatoid arthritis: a multiple treatment comparison regression analysis. *PLoS ONE* 2015;10(9):e0137258. DOI: 10.1371/journal.pone.0137258. [Context Link 1] View abstract...
79. van Vollenhoven RF, Felson D, Strand V, Weinblatt ME, Lijntens K, Keystone EC. American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: data from a 52-week phase III trial. *Arthritis Care & Research* 2011;63(1):128-134. DOI: 10.1002/acr.20331. [Context Link 1] View abstract...
80. Choy E, et al. Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. *Rheumatology* 2012;51(7):1226-1234. DOI: 10.1093/rheumatology/ker519. [Context Link 1] View abstract...
81. Weinblatt ME, et al. Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study. *Rheumatology* 2012;51(12):2204-2214. DOI: 10.1093/rheumatology/kes150. [Context Link 1] View abstract...
82. Remy A, Avouac J, Gossec L, Combe B. Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis. *Clinical and Experimental Rheumatology* 2011;29(1):96-103. [Context Link 1, 2] View abstract...

83. Schoels M, Aletaha D, Smolen JS, Wong JB. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor a inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. *Annals of the Rheumatic Diseases* 2012;71(8):1303-8. DOI: 10.1136/annrheumdis-2011-200490. [Context Link 1, 2] View abstract...
84. Fraenkel L, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. *Arthritis Care & Research* 2021;73(7):924-939. DOI: 10.1002/acr.24596. (Reaffirmed 2022 Aug) [Context Link 1, 2] View abstract...
85. Wells AF, Curtis JR, Betts KA, Douglas K, Du EX, Ganguli A. Systematic literature review and meta-analysis of tumor necrosis factor-alpha experienced rheumatoid arthritis. *Clinical Therapeutics* 2017;39(8):1680-1694.e2. DOI: 10.1016/j.clinthera.2017.06.013. [Context Link 1] View abstract...
86. Anderson J, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. *Arthritis Care & Research* 2012;64(5):640-7. DOI: 10.1002/acr.21649. [Context Link 1, 2, 3, 4, 5, 6, 7] View abstract...
87. Gilek-Seibert K, Prescott K, Kazi S. Outcome assessments in rheumatoid arthritis. *Current Rheumatology Reports* 2013;15(11):370. DOI: 10.1007/s11926-013-0370-y. [Context Link 1, 2, 3, 4, 5, 6, 7] View abstract...
88. Buzatu C, Moots RJ. Measuring disease activity and response to treatment in rheumatoid arthritis. *Expert Review of Clinical Immunology* 2019;15(2):135-145. DOI: 10.1080/1744666X.2019.1559050. [Context Link 1] View abstract...
89. Terrault NA, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *Hepatology* 2018;67(4):1560-1599. DOI: 10.1002/hep.29800. (Reaffirmed 2022 Apr) [Context Link 1, 2] View abstract...
90. Singh JA, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. *Cochrane Database of Systematic Reviews* 2011, (verified by Cochrane 2016 Apr), Issue 2. Art. No.: CD008794. DOI: 10.1002/14651858.CD008794.pub2. [Context Link 1, 2] View abstract...
91. Ramiro S, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. *Annals of the Rheumatic Diseases* 2014;73(3):529-535. DOI: 10.1136/annrheumdis-2013-204575. [Context Link 1] View abstract...
92. Singh JA, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. *Lancet* 2015;386(9990):258-265. DOI: 10.1016/S0140-6736(14)61704-9. [Context Link 1] View abstract...
93. Atzeni F, Batticciotto A, Masala IF, Talotta R, Benucci M, Sarzi-Puttini P. Infections and biological therapy in patients with rheumatic diseases. *Israel Medical Association Journal* 2016;18(3-4):164-167. [Context Link 1, 2] View abstract...
94. Bombardier C, et al. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. *Journal of Rheumatology* 2012;39(8):1583-1602. DOI: 10.3899/jrheum.120165. (Reaffirmed 2022 Jun) [Context Link 1, 2] View abstract...
95. Nast A, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 2: specific clinical and comorbid situations. *Journal of the European Academy of Dermatology and Venereology: JEADV*. 2021;35(2):281-317. DOI: 10.1111/jdv.16926. [Context Link 1] View abstract...
96. Hewitt RJ, Francis M, Singanayagam A, Kon OM. Screening tests for tuberculosis before starting biological therapy. *British Medical Journal* 2015;350:h1060. [Context Link 1] View abstract...
97. Bonovas S, et al. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. *Clinical Gastroenterology and Hepatology* 2016;14(10):1385-1397.e10. DOI: 10.1016/j.cgh.2016.04.039. [Context Link 1] View abstract...

Footnotes

[A] For patients with axial spondyloarthritis (ankylosing spondylitis, nonradiographic axial spondyloarthritis), certolizumab is administered as a subcutaneous injection and then repeated at weeks 2 and 4 after the initial injection.(1) [A in Context Link 1]

[B] Dactylitis is inflammation of an entire digit.(21) [B in Context Link 1, 2]

[C] Inflammatory back pain is characterized by an insidious onset of pain that improves with exercise, but not with rest, as well as nocturnal pain that improves upon getting up.(22) [C in Context Link 1, 2]

[D] For maintenance treatment of axial spondyloarthritis (ankylosing spondylitis, nonradiographic axial spondyloarthritis), certolizumab is administered as a subcutaneous injection every 2 to 4 weeks.(1) [D in Context Link 1]

[E] For initial treatment of Crohn disease, certolizumab is administered as a subcutaneous injection and then repeated at weeks 2 and 4 after the initial injection.(1) [E in Context Link 1]

[F] Crohn disease activity can be described by endoscopic findings, clinical symptoms, and the impact of the disease on a patient's quality of life; there is not a single accepted measurement of disease activity, although the Crohn's Disease Activity Index (CDAI) has often been used in clinical trials. Using clinical symptoms to categorize Crohn disease severity can help guide clinicians when making treatment decisions. Clinical remission usually corresponds to a CDAI score of less than 150. Mild to moderate disease usually corresponds to a CDAI score of 150 to 220, and moderate to severe disease usually corresponds to a CDAI score of 220 to 450. Severe to fulminant disease, despite the use of corticosteroids or biologic agents, usually corresponds to a CDAI score of greater than 450.(24)(27)(37) [F in Context Link 1]

[G] For maintenance treatment of Crohn disease, certolizumab is administered as a subcutaneous injection every 4 weeks after the initial set of induction injections.(1) [G in Context Link 1]

[H] For plaque psoriasis, certolizumab is administered as a subcutaneous injection every other week. It may also be administered as a subcutaneous injection and then repeated at weeks 2 and 4 after the initial injection.(1) [H in Context Link 1]

[I] For maintenance treatment of plaque psoriasis, certolizumab is administered as a subcutaneous injection every other week.(1) [I in Context Link 1]

[J] For patients with psoriatic arthritis, certolizumab is administered as a subcutaneous injection and then repeated every 2 weeks after the initial injection.(1) [J in Context Link 1]

[K] Dactylitis is characterized by diffuse swelling of a digit (either a finger or toe); it is a characteristic extra-articular manifestation of psoriatic arthritis.(51)(57) [K in Context Link 1]

[L] Enthesitis is characterized by inflammation at the site of tendon insertion; it is a characteristic extra-articular manifestation of psoriatic arthritis.(51)(57) [L in Context Link 1]

[M] For maintenance treatment of psoriatic arthritis, certolizumab is administered as a subcutaneous injection every 2 to 4 weeks.(1) [M in Context Link 1]

[N] For initial treatment of rheumatoid arthritis, certolizumab is administered as a subcutaneous injection initially and at weeks 2 and 4. (1) Certolizumab may be used concurrently with nonbiological disease-modifying antirheumatic drugs such as methotrexate.(1)(79) [N in Context Link 1]

[O] Rheumatoid arthritis disease activity should be evaluated by a validated tool that assesses disease severity; validated disease activity tools typically include a combination of patient self-assessment, physical examination of joints by a physician, and laboratory assessment of inflammatory response. An expert consensus recommendation supports use of the following instruments: the Clinical Disease Activity Index, the Disease Activity Score with 28-joint counts, the Patient Activity Scale (PAS), the PAS-II, the Routine Assessment of Patient Index Data 3, and the Simplified Disease Activity Index.(86)(87) [O in Context Link 1]

[P] The Clinical Disease Activity Index is a scale from 0 to 76 that uses physician joint count and both patient and physician global score to assess rheumatoid arthritis disease severity. A score of 2.8 or less indicates remission, while a score greater than 2.8 to 10 indicates low disease severity. Moderate disease activity is indicated by a score of greater than 10 to 22, and severe disease activity is indicated by a score of greater than 22.(86)(87) [P in Context Link 1]

[Q] The Disease Activity Score is a scale from 0 to 9.4 that is calculated by counting affected joints, the patient global score, and either the erythrocyte sedimentation rate or C-reactive protein level. A score of less than 2.6 indicates remission, while a score of 2.6 to less than 3.2 demonstrates low disease activity. Moderate disease activity is indicated by a score of 3.2 to 5.1, and severe disease activity is indicated by a score higher than 5.1.(86)(87) [Q in Context Link 1]

[R] The Patient Activity Scale and Patient Activity Scale-II consist of scales from 0 to 10 and use health assessment questionnaires to determine disease severity; they do not utilize affected joint counts or laboratory results. A score of 0.25 or less indicates remission. Low-severity disease is represented by a score of 0.26 to 3.7, and moderate disease activity is indicated by a score of 3.71 to less than 8. Severe disease activity is indicated by a score of 8 to 10.(86)(87) [R in Context Link 1, 2]

[S] The Routine Assessment of Patient Index Data 3 is a scale from 0 to 10 that is commonly used in clinical practice and uses a health assessment questionnaire and a patient global score to determine disease severity; it does not require joint counts or laboratory results. A score of 1 or less indicates remission. Low-severity disease is represented by a score greater than 1 to 2, and moderate disease activity is indicated by a score greater than 2 to 4. Severe disease activity is indicated by a score of greater than 4 to 10.(86)(87) [S in Context Link 1]

[T] The Simplified Disease Activity Index is a scale from 0 to 86 and is calculated by counting affected joints, the patient and provider global score, and the C-reactive protein level. A score of 3.3 or less indicates remission, while a score greater than 3.3 to 11 indicates low disease activity. Moderate disease activity is indicated by a score greater than 11 to 26, and severe disease activity is indicated by a score higher than 26.(86)(87) [T in Context Link 1]

[U] For maintenance treatment of rheumatoid arthritis, certolizumab is administered as a subcutaneous injection every 2 to 4 weeks after the initial set of induction injections.(1) For those showing no response after a total of 12 weeks of treatment, discontinuation should be considered.(62) [U in Context Link 1]

[V] Patients who are HBsAg positive are at high risk for reactivation of hepatitis B virus and should receive anti-HBV prophylaxis before initiating immunosuppressive or cytotoxic treatment. Patients who are HBsAg negative and HBcAb positive are at lower risk for reactivation and can be monitored closely for reactivation (eg, every 1 to 3 months) or started on anti-HBV prophylaxis, depending on the clinical situation.(89) [V in Context Link 1]

[W] An expert consensus guideline recommends that live vaccines should be administered at least 2 weeks, and ideally 4 weeks, before starting treatment with a biological disease-modifying antirheumatic drug.(94) [W in Context Link 1]

Codes

HCPCS: J0717

MCG Health
Ambulatory Care 27th Edition
Copyright © 2023 MCG Health, LLC
All Rights Reserved

Last Update: 9/21/2023 5:38:48 AM
Build Number: 27.2.2023092114759.013030